Publications by authors named "Eva De Lago"

Claim this Profile
A
Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy.
Marta Gomez-Almeria, Loreto Martinez-Gonzalez, Ana Teresa Matos, Carmen Rodriguez-Cueto, Ana Rita Vaz, Eva de Lago

Neuropharmacology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ageing, Neurodegeneration and the Endocannabinoid System.
Javier Fernández-Ruiz, Onintza Sagredo, María Gómez-Ruiz, Eva de Lago

Curr Top Behav Neurosci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB receptor activation in experimental ALS in male mice.
Marta Gómez-Almería, Claudia Gonzalo-Consuegra, Carmen Rodríguez-Cueto, María Cabañas-Cotillas, Alberto Jiménez-Amor, Eva de Lago

Cell Commun Signal· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.
Laura García-Toscano, Carmen Rodríguez-Cueto, Anna Furiano, William Hind, Eva de Lago

Biomed Pharmacother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays.
María Gómez-Cañas, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, Eva de Lago

Methods Mol Biol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia.
Ignacio Silva-Llanes, Raquel Martín-Baquero, Alicia Berrojo-Armisen, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, Eva De Lago

Antioxidants (Basel)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System Projects.
Johannes Aebi, Kenneth Atz, Simon M Ametamey, Jörg Benz, Julie Blaising, Eva De Lago

Chimia (Aarau)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involvement of CB and CB receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice.
Claudia Gonzalo-Consuegra, Irene Santos-García, Laura García-Toscano, Raquel Martín-Baquero, Carmen Rodríguez-Cueto, Eva de Lago

Biomed Pharmacother· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice.
Irene Santos-García, Carmen Rodríguez-Cueto, Patricia Villegas, Fabiana Piscitelli, Anna Lauritano, Eva de Lago

J Neuroinflammation· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations.
Ines Maestro, Laura R de la Ballina, Gracia Porras, Silvia Corrochano, Eva De Lago

Int J Mol Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
Isabel Lastres-Becker, Eva de Lago, Ana Martínez, Javier Fernández-Ruiz

Biomolecules· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Vanesa Nozal, Loreto Martínez-González, Marta Gomez-Almeria, Claudia Gonzalo-Consuegra, Paula Santana, Eva de Lago

J Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral Sclerosis.
Sonia Burgaz, Concepción García, Claudia Gonzalo-Consuegra, Marta Gómez-Almería, Francisco Ruiz-Pino, Eva de Lago

Molecules· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactivation of the CB receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis.
Carmen Rodríguez-Cueto, Marta Gómez-Almería, Laura García Toscano, Julián Romero, Cecilia J Hillard, Eva de Lago

Brain Pathol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis.
Marta Gómez-Almería, Sonia Burgaz, Carlos Costas-Insua, Carmen Rodríguez-Cueto, Irene Santos-García, Eva de Lago

Int J Mol Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis.
Loreto Martínez-González, Claudia Gonzalo-Consuegra, Marta Gómez-Almería, Gracia Porras, Eva de Lago

Int J Mol Sci· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the CB receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis.
Carmen Rodríguez-Cueto, Laura García-Toscano, Irene Santos-García, Marta Gómez-Almería, Claudia Gonzalo-Consuegra, Eva de Lago

Br J Pharmacol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis.
Javier Fernández-Ruiz, Eva de Lago, Carmen Rodríguez-Cueto, María A Moro

Br J Pharmacol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis.
Pilar Rojas, Ana I Ramírez, Manuel Cadena, José A Fernández-Albarral, Elena Salobrar-García, Eva de Lago

Int J Mol Sci· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis.
Elisa Rojas-Prats, Loreto Martinez-Gonzalez, Claudia Gonzalo-Consuegra, Nicole F Liachko, Concepción Perez, Eva de Lago

Eur J Med Chem· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment.
Loreto Martínez-González, Carmen Rodríguez-Cueto, Diego Cabezudo, Fernando Bartolomé, Pol Andrés-Benito, Eva de Lago

Sci Rep· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
María Fernández-Trapero, Carmen Pérez-Díaz, Francisco Espejo-Porras, Eva de Lago, Javier Fernández-Ruiz

Biomolecules· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting glial cannabinoid CB receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis.
Francisco Espejo-Porras, Laura García-Toscano, Carmen Rodríguez-Cueto, Irene Santos-García, Eva de Lago

Br J Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1 transgenic mice, an experimental model of amyotrophic lateral sclerosis.
Carmen Rodríguez-Cueto, Irene Santos-García, Laura García-Toscano, Francisco Espejo-Porras, MLuz Bellido, Eva de Lago

Biochem Pharmacol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients.
Francisco Espejo-Porras, Javier Fernández-Ruiz, Eva de Lago

Amyotroph Lateral Scler Frontotemporal Degener· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis